Atlas Trials

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Clinical trial NCT05128773 · TERMINATED

Trial details

NCT number
NCT05128773
Sponsor
Sanofi
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2022-02-17
Primary completion
2022-10-13
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.